Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report

The most important goal of treatment of patients with metastatic breast cancer is maintenance or even improvement of quality of life. In this setting, chemotherapy should be used with as much restraint as possible. If palliative chemotherapy is indicated, the taxane drug class is an established trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Gluz, Oleg, Kolberg-Liedtke, Cornelia, Marmé, Frederik, Thill, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174001/
https://www.ncbi.nlm.nih.gov/pubmed/32322109
http://dx.doi.org/10.1055/a-1126-4247
_version_ 1783524551280295936
author Gluz, Oleg
Kolberg-Liedtke, Cornelia
Marmé, Frederik
Thill, Marc
author_facet Gluz, Oleg
Kolberg-Liedtke, Cornelia
Marmé, Frederik
Thill, Marc
author_sort Gluz, Oleg
collection PubMed
description The most important goal of treatment of patients with metastatic breast cancer is maintenance or even improvement of quality of life. In this setting, chemotherapy should be used with as much restraint as possible. If palliative chemotherapy is indicated, the taxane drug class is an established treatment option. The updated guidelines of the Gynaecological Oncology Working Group (AGO), Breast Committee, of the German Society for Gynaecology and Obstetrics (DGGG) and the German Cancer Society e. V. (DKG) provide recommendations with the greatest possible evidence on which of the licensed taxanes can be used in which treatment situation in the metastatic setting.
format Online
Article
Text
id pubmed-7174001
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-71740012020-04-22 Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report Gluz, Oleg Kolberg-Liedtke, Cornelia Marmé, Frederik Thill, Marc Geburtshilfe Frauenheilkd The most important goal of treatment of patients with metastatic breast cancer is maintenance or even improvement of quality of life. In this setting, chemotherapy should be used with as much restraint as possible. If palliative chemotherapy is indicated, the taxane drug class is an established treatment option. The updated guidelines of the Gynaecological Oncology Working Group (AGO), Breast Committee, of the German Society for Gynaecology and Obstetrics (DGGG) and the German Cancer Society e. V. (DKG) provide recommendations with the greatest possible evidence on which of the licensed taxanes can be used in which treatment situation in the metastatic setting. Georg Thieme Verlag KG 2020-04 2020-04-21 /pmc/articles/PMC7174001/ /pubmed/32322109 http://dx.doi.org/10.1055/a-1126-4247 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Gluz, Oleg
Kolberg-Liedtke, Cornelia
Marmé, Frederik
Thill, Marc
Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
title Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
title_full Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
title_fullStr Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
title_full_unstemmed Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
title_short Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
title_sort use of taxanes in metastatic her2-negative breast cancer – a status report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174001/
https://www.ncbi.nlm.nih.gov/pubmed/32322109
http://dx.doi.org/10.1055/a-1126-4247
work_keys_str_mv AT gluzoleg useoftaxanesinmetastaticher2negativebreastcancerastatusreport
AT kolbergliedtkecornelia useoftaxanesinmetastaticher2negativebreastcancerastatusreport
AT marmefrederik useoftaxanesinmetastaticher2negativebreastcancerastatusreport
AT thillmarc useoftaxanesinmetastaticher2negativebreastcancerastatusreport

Ejemplares similares